Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Tolerance

Tolerance

21

Pipeline Programs↗

12

Active Trials↗

51

Companies Involved↗

Tolerance is an emerging landscape with 21 programs across 51 companies.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

85/100

Attrition Rate

11/100

Pipeline

Programs by Phase

Preclinical17

Oxytocin Treatment

University of Electronic Science and Technology of China

Intramuscular Injections of Morphine

University of California, San Francisco

Experimental

Biogen

Tazorac

Fougera Pharmaceuticals Inc.

Dove Mild Cleanser

University of Michigan

Phase 1

No programs

Phase 24

JB-101

Juntendo University

Favipiravir

Appili Therapeutics Inc.

Hetrombopag Olamine

Jiangsu HengRui Medicine Co., Ltd.

Aspirin

Bayer

Phase 3

No programs

Approved

No programs

Analysis

Modality Breakdown

95%

Small molecule

18 of 19 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 21 pipeline programs.

Analysis

Trial Status

233

clinical trials

Completed149 · 64%

Unknown status45 · 19%

Terminated20 · 9%

Recruiting9 · 4%

Withdrawn5 · 2%

Not yet recruiting2 · 1%

Other3 · 1%

Clinical Trials

Trial Activity

233 trials

Risk Factors for Poor Tolerance of Ureteral Double-J Stent

Recruiting·CCentre Hospitalier Universitaire, Amiens·Preclinical·NCT06815107·200 enrolled

Immunoregulatory Factors in Human Breast Milk: Relationship Between Regulatory T Cells (Tregs), miRNAs and Food Tolerance

Recruiting·IIstanbul University·N/A·NCT07744373·25 enrolled

Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

Recruiting·YYale University·Phase 1·NCT05906511·20 enrolled

Phase I Study of Combined Deceased Donor Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment

Recruiting·SStanford University·Phase 1·NCT04571203·30 enrolled

Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion to Withdraw Immunosuppressive Drugs From Recipients of a Previous HLA Matched Living Donor Kidney Transplantation .

Recruiting·—·Phase 1·NCT03591302·25 enrolled

Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates

Recruiting·—·N/A·NCT07088302·120 enrolled

Evaluation of Tolerance and Pharmacokinetic Profile of High Doses of Favipiravir in Healthy Volunteers

Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1·NCT06024421·39 enrolled

Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial

Recruiting·MMorehouse School of Medicine·Phase 4·NCT07215000·300 enrolled

TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06478537·56 enrolled

Induction of Transplant Tolerance in LDLT Via iTS

Active, not recruiting·JJuntendo University·Phase 1/2·NCT04950842·10 enrolled

Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1)

Not yet recruiting·KKing's College London·N/A·NCT07471347·10 enrolled

Preliminary Safety and Efficacy Study of Extracellular Vesicle Infusion in the Intervention of Age-related Phenotypes With Impaired Glucose Tolerance.

Not yet recruiting·BBEAUTECH·N/A·NCT06495437·20 enrolled

Effect of Adding Continuous Glucose Monitoring (CGM) to Lifestyle Changes on Insulin Sensitivity in Patients With Impaired Glucose Tolerance

Completed·NNemours Children's Clinic·Preclinical·NCT05387551·12 enrolled

Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy

Completed·SState University of New York - Upstate Medical University·Phase 4·NCT06219967·5 enrolled

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

Completed·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT05270928·6 enrolled

Page 1 of 16

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)